Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech acquired 50,000 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were bought at an average cost of $36.75 per share, for a total transaction of $1,837,500.00. Following the completion of the acquisition, the insider now directly owns 5,298,799 shares of the company’s stock, valued at $194,730,863.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Radius Health, Inc. (RDUS) traded down 2.21% on Thursday, reaching $36.25. 577,791 shares of the company were exchanged. Radius Health, Inc. has a 52 week low of $31.58 and a 52 week high of $59.22. The stock has a 50-day moving average price of $38.85 and a 200 day moving average price of $39.47. The stock’s market capitalization is $1.58 billion.

Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by $0.23. The business had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same period in the prior year, the firm posted ($1.01) EPS. Analysts forecast that Radius Health, Inc. will post ($5.51) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Insider Buying: Radius Health, Inc. (RDUS) Major Shareholder Acquires 50,000 Shares of Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/07/insider-buying-radius-health-inc-rdus-major-shareholder-acquires-50000-shares-of-stock.html.

A number of equities research analysts have recently weighed in on RDUS shares. Cantor Fitzgerald set a $65.00 price objective on shares of Radius Health and gave the company a “buy” rating in a report on Monday, May 22nd. Maxim Group set a $24.00 price objective on shares of Radius Health and gave the company a “sell” rating in a report on Wednesday, May 24th. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Canaccord Genuity reissued a “buy” rating and set a $85.00 price objective on shares of Radius Health in a report on Monday, May 22nd. Finally, BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $53.60.

Institutional investors and hedge funds have recently made changes to their positions in the business. Ameritas Investment Partners Inc. acquired a new position in Radius Health during the first quarter worth about $105,000. Sei Investments Co. raised its position in Radius Health by 27.7% during the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 690 shares during the last quarter. Advisor Group Inc. raised its position in Radius Health by 267.2% during the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 2,888 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Radius Health by 1.1% during the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after acquiring an additional 46 shares during the last quarter. Finally, Blair William & Co. IL acquired a new position in Radius Health during the second quarter worth about $205,000.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.